Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
3.960
-0.040 (-1.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Senti Biosciences Employees
Senti Biosciences had 48 employees as of December 31, 2023. The number of employees decreased by 74 or -60.66% compared to the previous year.
Employees
48
Change (1Y)
-74
Growth (1Y)
-60.66%
Revenue / Employee
n/a
Profits / Employee
-$1,477,000
Market Cap
18.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 48 | -74 | -60.66% |
| Dec 31, 2022 | 122 | 33 | 37.08% |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SNTI News
- 2 months ago - Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics - GlobeNewsWire
- 2 months ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Benzinga
- 2 months ago - Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - GlobeNewsWire
- 2 months ago - Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - GlobeNewsWire
- 3 months ago - Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - GlobeNewsWire
- 6 months ago - Senti Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - GlobeNewsWire